Evidence map›Paper›PMID 39871788›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

PEARL: Protein Eluting Alginate with Recombinant Lactobacilli.

Varun Sai Tadimarri, Marc Blanch-Asensio, Ketaki Deshpande, Jonas Baumann, Carole Baumann, Rolf Müller, Sara Trujillo, Shrikrishnan Sankaran

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Probiotic-Based Materials as Living Therapeutics.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  4. Developing anACS pharmacology & translational science · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Varun Sai TadimarriINM - Leibniz Institute for New Materials, Saarland University, Campus D2 2, 66123, Saarbrücken, Germany.
Marc Blanch-AsensioINM - Leibniz Institute for New Materials, Saarland University, Campus D2 2, 66123, Saarbrücken, Germany.
Ketaki DeshpandeINM - Leibniz Institute for New Materials, Saarland University, Campus D2 2, 66123, Saarbrücken, Germany.
Jonas BaumannHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, Campus E8 1, 66123, Saarbrücken, Germany.
Carole BaumannHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland University, Campus E8 1, 66123, Saarbrücken, Germany.
Rolf MüllerSaarland University, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0002-1042-5665
Sara TrujilloINM - Leibniz Institute for New Materials, Saarland University, Campus D2 2, 66123, Saarbrücken, Germany.
Shrikrishnan SankaranINM - Leibniz Institute for New Materials, Saarland University, Campus D2 2, 66123, Saarbrücken, Germany.ORCID https://orcid.org/0000-0001-6251-585X

Funding

Deutsche Forschungsgemeinschaft 200049484Deutsche Forschungsgemeinschaft SFB1027Leibniz-Gemeinschaft LeibnizScienceCampusLivingTherapeuticMaterials(LifeMat)
6 · The paper itself

Abstract

Engineered living materials (ELMs) made of bacteria in hydrogels have shown considerable promise for therapeutic applications through controlled and sustained release of complex biopharmaceuticals at low costs and with reduced wastage. While most therapeutic ELMs use E. coli due to its large genetic toolbox, most live biotherapeutic bacteria in development are lactic acid bacteria due to native health benefits they offer. Among these, lactobacilli form the largest family of probiotics with therapeutic potential in almost all sites of the body with a microbiome. A major factor limiting the use of lactobacilli in ELMs is their limited genetic toolbox. This study expands on recent work to expand the genetic programmability of probiotic Lactiplantibacillus plantarum WCFS1 for protein secretion and encapsulate it in a simple, cost-effective, and biocompatible core-shell alginate bead to develop an ELM. The controlled release of recombinant proteins is demonstrated, even up to 14 days from this ELM, thereby terming it PEARL - Protein Eluting Alginate with Recombinant Lactobacilli. Notably, lactobacillus encapsulation offered benefits like bacterial containment, protein release profile stabilization, and metabolite-induced cytotoxicity prevention. These findings demonstrate the mutual benefits of combining recombinant lactobacilli with alginate for the controlled and sustained release of proteins.

Indexed as

AlginatesLactobacillusRecombinant ProteinsProbioticsAlginatesRecombinant Proteinsalginateengineered living materialslactobacillussecretionsynthetic biology

Identifiers

PMID39871788
PMCPMC12994548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.